Company SENN AB Nasdaq Stockholm
Equities
SE0010219626
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Genomic Allergen Rapid Detection
100.0
%
| 42 | 100.0 % | 50 | 100.0 % | +19.39% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 42 | 100.0 % | 50 | 100.0 % | +19.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 31/12/17 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 31/10/16 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 31/12/13 |
Director/Board Member | 59 | 14/10/14 | |
Public Communications Contact | 56 | 31/12/17 | |
Helen Olsson
HRO | Human Resources Officer | 59 | 31/12/19 |
Corporate Officer/Principal | 51 | 31/12/16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 17/08/10 | |
Director/Board Member | 59 | 14/10/14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 31/12/19 |
Director/Board Member | 65 | 31/12/19 | |
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 31/12/17 |
Ian Kimber
BRD | Director/Board Member | 74 | 31/12/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 24,188,325 | 14,889,392 ( 61.56 %) | 0 | 61.56 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-27.31% | 9.88B | |
+28.35% | 2.89B | |
-14.34% | 2.88B | |
-15.31% | 2.12B | |
-19.92% | 1.67B | |
+74.27% | 1.45B | |
+29.92% | 788M | |
-5.02% | 741M | |
-27.76% | 514M |